Mark S Hixon

List of Publications by Year
in descending order

55 papers	1,498 citations	257450 24 h-index	345221 36 g-index
58 all docs	58 docs citations	58 times ranked	1764 citing authors

#	Article	IF	Citations
1	An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 2602-2607.	7.1	119
2	Structures of Clostridium botulinum Neurotoxin Serotype A Light Chain Complexed with Small-Molecule Inhibitors Highlight Active-Site Flexibility. Chemistry and Biology, 2007, 14, 533-542.	6.0	119
3	Synthesis, Characterization and Development of a High-Throughput Methodology for the Discovery of Botulinum Neurotoxin A Inhibitors. ACS Combinatorial Science, 2006, 8, 513-521.	3.3	67
4	Metabolomics-Based Discovery of Diagnostic Biomarkers for Onchocerciasis. PLoS Neglected Tropical Diseases, 2010, 4, e834.	3.0	66
5	Onchocerca volvulus -neurotransmitter tyramine is a biomarker for river blindness. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 4218-4223.	7.1	63
6	Botulinum Neurotoxin A Protease: Discovery of Natural Product Exosite Inhibitors. Journal of the American Chemical Society, 2010, 132, 2868-2869.	13.7	49
7	NB2001, a Novel Antibacterial Agent with Broad-Spectrum Activity and Enhanced Potency against Î²-Lactamase-Producing Strains. Antimicrobial Agents and Chemotherapy, 2002, 46, 1262-1268.	3.2	45
8	Catalytic antibody degradation of ghrelin increases whole-body metabolic rate and reduces refeeding in fasting mice. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 17487-17492.	7.1	43
9	Monoclonal Antibodies for Combating Synthetic Opioid Intoxication. Journal of the American Chemical Society, 2019, 141, 10489-10503.	13.7	43
10	Rapid Determination of the Specificity Constant of Irreversible Inhibitors (k_{inact}/K_I) by Means of an Endpoint Competition Assay. Angewandte Chemie - International Edition, 2015, 54, 14099-14102.	13.8	42
11	Identification of a Natural Product Antagonist against the Botulinum Neurotoxin Light Chain Protease. ACS Medicinal Chemistry Letters, 2010, 1, 268-272.	2.8	40
12	Discovery of Acetylcholinesterase Peripheral Anionic Site Ligands through Computational Refinement of a Directed Library. Biochemistry, 2005, 44, 14845-14853.	2.5	36
13	Probing Active Cocaine Vaccination Performance through Catalytic and Noncatalytic Hapten Design. Journal of Medicinal Chemistry, 2013, 56, 3701-3709.	6.4	36
14	Identification and Characterization of Single Chain Anti-cocaine Catalytic Antibodies. Journal of Molecular Biology, 2007, 365, 722-731.	4.2	35
15	Biochemical Characterization of TAK-593, a Novel VEGFR/PDGFR Inhibitor with a Two-Step Slow Binding Mechanism. Biochemistry, 2011, 50, 738-751.	2.5	35
16	Quo vadis photorespiration: A tale of two aldolases. FEBS Letters, 1996, 392, 281-284.	2.8	31
17	Toward the discovery of potent inhibitors of botulinum neurotoxin A: development of a robust LC MS based assay operational from low to subnanomolar enzyme concentrations. Chemical Communications, 2008, , 3525.	4.1	30
18	Probing the Effects of Hapten Stability on Cocaine Vaccine Immunogenicity. Molecular Pharmaceutics, 2013, 10, 4176-4184.	4.6	29

#	Article	IF	Citations
19	ATP Allosterically Activates the Human 5-Lipoxygenase Molecular Mechanism of Arachidonic Acid and 5(S)-Hydroperoxy-6(E),8(Z),11(Z),14(Z)-eicosatetraenoic Acid. Biochemistry, 2014, 53, 4407-4419.	2.5	29
20	Noninvasive Urine Biomarker Lateral Flow Immunoassay for Monitoring Active Onchocerciasis. ACS Infectious Diseases, 2018, 4, 1423-1431.	3.8	29
21	Chirality Holds the Key for Potent Inhibition of the Botulinum Neurotoxin Serotype A Protease. Organic Letters, 2010, 12, 756-759.	4.6	28
22	Benzylidene cyclopentenediones: First irreversible inhibitors against botulinum neurotoxin Aâ€™s zinc endopeptidase. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 206-208.	2.2	27
23	Discovery of novel benzo[b][1,4]oxazin-3(4H)-ones as poly(ADP-ribose)polymerase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 4501-4505.	2.2	27
24	A Back-to-Front Fragment-Based Drug Design Search Strategy Targeting the DFG-Out Pocket of Protein Tyrosine Kinases. ACS Medicinal Chemistry Letters, 2012, 3, 342-346.	2.8	25
25	General Method for the Study of Solute-Surfactant Association Equilibria of Volatile Solutes by Head Space Gas Chromatography. Analytical Chemistry, 1995, 67, 1459-1464.	6.5	23
26	Zum Mechanismus der metallabhÃngigen Aldolasen der Klasse II. Angewandte Chemie, 1996, 108, 2366-2369.	2.0	23
27	Mechanistic Insights into the LsrK Kinase Required for Autoinducer-2 Quorum Sensing Activation. Journal of the American Chemical Society, 2013, 135, 7827-7830.	13.7	22
28	Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: Comparison of binding to non-phosphorylated and phosphorylated VEGFR2. Bioorganic and Medicinal Chemistry, 2011, 19, 5342-5351.	3.0	21
29	Solid-Phase Synthesis and Kinetic Characterization of Fluorogenic Enzyme-Degradable Hydrogel Cross-linkers. Biomacromolecules, 2006, 7, 1011-1016.	5.4	20
30	Fragment-based drug discovery of potent and selective MKK3/6 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 1086-1089.	2.2	20
31	Superactivation of the Botulinum Neurotoxin Serotype A Light Chain Metalloprotease:Â A New Wrinkle in Botulinum Neurotoxin. Journal of the American Chemical Society, 2006, 128, 4176-4177.	13.7	19
32	Identification of Î±₂â€…Macroglobulin as a Major Serum Ghrelin Esterase. Angewandte Chemie - International Edition, 2011, 50, 10699-10702.	13.8	19
33	A cross-over inhibitor of the botulinum neurotoxin light chain B: a natural product implicating an exosite mechanism of action. Chemical Communications, 2011, 47, 1713.	4.1	18
34	Formulating a new basis for the treatment against botulinum neurotoxin intoxication: 3,4-Diaminopyridine prodrug design and characterization. Bioorganic and Medicinal Chemistry, 2011, 19, 6203-6209.	3.0	18
35	Benzoquinones as inhibitors of botulinum neurotoxin serotype A. Bioorganic and Medicinal Chemistry, 2014, 22, 3971-3981.	3.0	17
36	C-Terminus of Botulinum A Protease Has Profound and Unanticipated Kinetic Consequences upon the Catalytic Cleft. ACS Medicinal Chemistry Letters, 2013, 4, 283-287.	2.8	16

#	Article	IF	Citations
37	Toward the discovery of dual inhibitors for botulinum neurotoxin A: concomitant targeting of endocytosis and light chain protease activity. Chemical Communications, 2015, 51, 6226-6229.	4.1	15
38	Development of a FRET Assay for Monitoring of HIV gp41 Core Disruption. Journal of Organic Chemistry, 2007, 72, 6700-6707.	3.2	14
39	Design, synthesis and optimization of 7-substituted-pyrazolo[4,3-b]pyridine ALK5 (activin receptor-like) Tj ETQq1 1 0.784314 rgBT /O	2.2	13
40	Repurposing Suzuki Coupling Reagents as a Directed Fragment Library Targeting Serine Hydrolases and Related Enzymes. Journal of Medicinal Chemistry, 2017, 60, 5209-5215.	6.4	12
41	MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody. Molecular Cancer Therapeutics, 2017, 16, 1269-1278.	4.1	11
42	Antipsychotic Benzamides Amisulpride and LB-102 Display Polypharmacy as Racemates, S Enantiomers Engage Receptors D₂ and D₃, while R Enantiomers Engage 5-HT₇. ACS Omega, 2019, 4, 14151-14154.	3.5	11
43	Probing BoNT/A Protease Exosites: Implications for Inhibitor Design and Light Chain Longevity. Biochemistry, 2014, 53, 6820-6824.	2.5	9
44	A Fragment-Based Approach to Identifying S-Adenosyl-<scp>l</scp>-methionine -Competitive Inhibitors of Catechol O-Methyl Transferase (COMT).. Journal of Medicinal Chemistry, 2014, 57, 5459-5463.	6.4	9
45	Design, synthesis and optimization of novel Alk5 (activin-like kinase 5) inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4334-4339.	2.2	9
46	T-3364366 Targets the Desaturase Domain of Delta-5 Desaturase with Nanomolar Potency and a Multihour Residence Time. ACS Medicinal Chemistry Letters, 2016, 7, 868-872.	2.8	8
47	Synthetic molecules for disruption of the MYC protein-protein interface. Bioorganic and Medicinal Chemistry, 2018, 26, 4234-4239.	3.0	8
48	NMR detection of adventitious xylose binding to the quorum-sensing protein SdiA of Escherichia coli. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 6202-6205.	2.2	7
49	Salicylanilide Analog Minimizes Relapse of Clostridioides difficile Infection in Mice. Journal of Medicinal Chemistry, 2020, 63, 6898-6908.	6.4	7
50	Synthesis and Application of a Novel Ligand for Affinity Chromatography Based Removal of Endotoxin from Antibodies. Bioconjugate Chemistry, 2007, 18, 559-566.	3.6	5
51	A Platform Stratifying a Sequestering Agent and a Pharmacological Antagonist as a Means to Negate Botulinum Neurotoxicity. ACS Chemical Neuroscience, 2014, 5, 632-636.	3.5	4
52	A randomized, double-blind, placebo controlled, phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of LB-102, a selective dopamine D2/3/5-HT7 inhibitor. Psychopharmacology, 2022, 239, 3009-3018.	3.1	3
53	A simple and widely applicable hit validation strategy for proteinâ€“protein interaction inhibitors based on a quantitative ligand displacement assay. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 5836-5839.	2.2	2
54	Identification of Slow-Binding Inhibitors of the BoNT/A Protease. ACS Medicinal Chemistry Letters, 2022, 13, 742-747.	2.8	2

#	Article	IF	Citations
55	Synthetic fluorescent MYC probe: Inhibitor binding site elucidation and development of a high-throughput screening assay. Bioorganic and Medicinal Chemistry, 2021, 42, 116246.	3.0	1